Newsletter
1 de June de 2012
- Kasznar Leonardos
Newsletter 2012.03 – The debate over ANVISA’s role in the examination of pharmaceutical patent applications continues
As you may be aware, due to article 229-C of the Brazilian IP Law, as amended by Law No. 10,196/01, whenever a patent application claims a pharmaceutical product or process, consent from the National Sanitary Surveillance Agency (ANVISA) is also required prior to granting the desired patent. This provision, however, has been the source of never-ending controversy and subject to growing attacks since it entered into effect in 2001.
The lack of statutory power of ANVISA to analyse patentability requirements of pharma applications was supported by the Attorney-General’s Office in legal opinions published in 2009 and 2011. Indeed, in their opinion, ANVISA should only make health-based assessments of applications sent for prior consent; prior consent should only be denied to applications in instances that granting the patents would pose health risks. How ANVISA would assess “health risks” on the basis of the information included in patent applications was left unanswered though.
Last related news
6 de May de 2025
Legal Protection for Developers: Compensation for Irregular Licenses
Our firm recently secured another important court victory on behalf of a software developer client in a lawsuit against a company that … Legal Protection for Developers: Compensation for Irregular Licenses
24 de April de 2025
Third Parties and Software Piracy: Companies Remain Legally Responsible
During software compliance audits, it is not uncommon for companies to claim that pirated programs were installed by external contractors or IT … Third Parties and Software Piracy: Companies Remain Legally Responsible
16 de April de 2025
Medicinal Cannabis Review: Public Consultation 1.316/2025 open
The Public Consultation (CP) No. 1.316/2025, which aims to initiate the review process of Collegiate Board Resolution (RDC) No. 327/2019 from the … Medicinal Cannabis Review: Public Consultation 1.316/2025 open